Since TYR, TYRP1, TYRP2, PMEL, and MELAN-A are recognised as melanocyte differentiation antigens (MDAs), inhibition of BRAF V600E increases MDAs expression, through the upregulation of MITF, enhancing melanoma immunogenicity [49]. The gene discussed is BRAF; the disease is melanoma.